Does Cigna Cover GLP-1 Medications? (2026)
Coverage rules, copays, prior auth requirements, and appeal options for Cigna members seeking Wegovy, Ozempic, Zepbound, or Mounjaro.
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. How we make money
Coverage by Medication[8]
| Medication | Cigna Coverage |
|---|---|
| Wegovy (semaglutide) | Cigna covers Wegovy on many commercial plans with prior authorization (standalone policy IP0814 for Wegovy injection and Wegovy HD, effective 09/01/2026; Wegovy tablets moved to a separate policy, IP0815). Adult initial approval is 8 months if patient is >=18, has engaged in >=3 months of behavioral modification and dietary restriction, has BMI >=30 OR BMI >=27 with one of 11 weight-related comorbidities (hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea, cardiovascular disease, knee osteoarthritis, asthma, COPD, MASLD/NAFLD, polycystic ovarian syndrome, or coronary artery disease), and uses Wegovy concomitantly with a reduced-calorie diet. Continuation/reauthorization is 1 year and requires documented >=5% baseline body-weight loss. Pediatric (>=12 to <18) initial 8-month approval requires BMI >=95th percentile + 3-month behavioral/diet trial; continuation requires >=1% BMI reduction. A separate MACE risk-reduction pathway (1-year approval) covers patients >=18 with BMI >=27 and established cardiovascular disease (prior heart attack, prior stroke other than TIA, or symptomatic peripheral arterial disease), with no weight-loss requirement. Some Cigna plans use stricter GLP-1 weight-loss policies with higher BMI floors: IP0621 (BMI >=32) and IP0739 (BMI >=35), so the threshold depends on the plan. |
| Ozempic (semaglutide) | Covered for type 2 diabetes per CNF 360 (last selected revision 01/07/2026). Step therapy gate (verbatim): if criteria for previous use of an oral diabetes medication in the past 130 days are not met, OR patient is <18, coverage requires prior authorization. CRITICAL: single-entity metformin and Rybelsus do NOT satisfy the 130-day step. PA approval is 1 year if patient is >=18. |
| Zepbound (tirzepatide) | Covered per standalone policy IP0816 (effective 09/01/2026) with the same 4-prong adult initial criteria as Wegovy: >=18, 3-month behavioral/diet trial, BMI >=30 OR BMI >=27 with one of the 11 comorbidities, concomitant lifestyle. Initial approval is 8 months; continuation is 1 year and requires >=5% baseline body-weight loss. Separate moderate-to-severe OSA-in-obesity pathway (1-year initial) requires AHI (or respiratory event index) >=15 by sleep study, BMI >=30, and no central sleep apnea / Cheyne-Stokes; OSA continuation requires >=10% body-weight loss after >=1 year plus prescriber-attested OSA stability. Quantity limits per CNF 840 (current): 4 pens or vials (2 mL) per 28 days or 12 pens or vials (6 mL) per 84 days, with no overrides recommended, across all strengths. |
| Mounjaro (tirzepatide) | Covered for type 2 diabetes per CNF 360 (last selected revision 01/07/2026). Step therapy gate (verbatim): if criteria for previous use of an oral diabetes medication in the past 130 days are not met, OR patient is <10 years of age, coverage requires prior authorization. CRITICAL: single-entity metformin and Rybelsus do NOT satisfy the step — a different oral antidiabetic must be in the lookback. PA approval is 1 year if patient is >=10 years of age. (Mounjaro minimum age was lowered from >=18 to >=10 effective 01/07/2026 per the policy History note.) |
| Foundayo (orforglipron) | Covered per IP0206, which since 09/01/2026 is Cigna's Foundayo-only policy (Wegovy, Zepbound, and Saxenda moved to their own policies). Same 4-prong adult initial framework as Wegovy/Zepbound: >=18, 3-month behavioral/diet trial, BMI >=30 OR BMI >=27 with one of the 11 weight-related comorbidities, concomitant lifestyle. Initial approval is 8 months; continuation is 1 year and requires documented >=5% baseline body-weight loss. IP0206 is the canonical source. |
| Typical copay (when covered) | $25-$75 / month |
If You're Denied by Cigna
If Cigna denies coverage for Wegovy or Zepbound, you still have affordable options. Compounded semaglutide and tirzepatide are dispensed by licensed 503A pharmacies[7] and cost $149-$299/month — a fraction of brand-name pricing. Brand-name GLP-1 medications are generally an HSA/FSA-eligible medical expense with a prescription[5], and many plan administrators also accept compounded GLP-1s with a Letter of Medical Necessity. The providers below ship to all 50 states and offer same-week prescriptions.
Many large employers offer self-funded health plans governed by ERISA rather than state insurance law, which gives them discretion over whether to cover anti-obesity medications[6]. If your employer self-funds its plan, check the Summary Plan Description for the specific GLP-1 coverage language.
Before going cash-pay, file a formal appeal with Cigna. Many denials are overturned with a Letter of Medical Necessity from your prescriber documenting BMI, comorbidities, and prior failed weight-loss attempts.
For the literal text of every Cigna GLP-1 PA clause — the 11-condition comorbidity list, the 130-day step-therapy rule that excludes single-entity metformin, the Mounjaro ≥10-year-old change, the Zepbound OSA pathway, the Wegovy MACE pathway, the Foundayo (orforglipron) handling, and the CNF 840 quantity limits — see our Cigna GLP-1 Prior Authorization Guide.
Top cash-pay GLP-1 providers if Cigna won't cover it
Compounded semaglutide and tirzepatide are widely available on a cash-pay basis — often for less than a plan's copay after a denial. These are our top-ranked picks, followed by a fuller list of alternatives.
Top picks
| # | Provider | Score | |
|---|---|---|---|
| 1 | CoreAge Rx | Get started | |
| 2 | Collective | Get started | |
| 3 | Found | Get started | |
| 4 | Gala | Get started | |
| 5 | bmiMD | Get started |
Compare the top providers at a glance
Logos, our editorial rating, price, medications, and coverage — the fastest way to narrow the list.
- ★ Editor's Pick
lowest-price compounded semaglutide and tirzepatide with one flat price at every dose
From /mo$79Flat at every doseCoverage50 statesMedicationsSemaglutideTirzepatide - Best Budget
the lowest flat medication price if you can absorb an annual membership fee
From /mo$59Flat at every doseCoverage44 statesMedicationsSemaglutideTirzepatide - Nationwide Coverage
medication-included compounded GLP-1 from $169/mo on a 12-month prepaid plan, plus brand insurance help
From /mo$149Coverage50 statesMedicationsSemaglutideTirzepatideOrforglipron compounded semaglutide or tirzepatide at one all-doses price on a yearly plan, with free shipping
From /mo$129Flat at every doseCoverage50 statesMedicationsSemaglutideTirzepatideone flat compounded GLP-1 price at every dose: semaglutide $159/mo month to month, $119/mo on a 12-month plan
From /mo$159Flat at every doseCoverage50 statesMedicationsSemaglutideTirzepatide
| Provider | Rating | From /mo | Medications | Coverage | |
|---|---|---|---|---|---|
| ★ Editor's Pick lowest-price compounded semaglutide and tirzepatide with one flat price at every dose | $79 Flat pricing | SemaglutideTirzepatide | 50 states | Get started → | |
| Best Budget the lowest flat medication price if you can absorb an annual membership fee | $59 Flat pricing | SemaglutideTirzepatide | 44 states | Get started → | |
| Nationwide Coverage medication-included compounded GLP-1 from $169/mo on a 12-month prepaid plan, plus brand insurance help | $149 | SemaglutideTirzepatideOrforglipron | 50 states | Get started → | |
compounded semaglutide or tirzepatide at one all-doses price on a yearly plan, with free shipping | $129 Flat pricing | SemaglutideTirzepatide | 50 states | Get started → | |
one flat compounded GLP-1 price at every dose: semaglutide $159/mo month to month, $119/mo on a 12-month plan | $159 Flat pricing | SemaglutideTirzepatide | 50 states | Get started → |
More compounded alternatives
Editorial score · methodology
Aurelius Health Group
Best for: transparent, care-inclusive compounded tirzepatide microdosing
Editorial score · methodology
Boston Medical Group
Best for: men's health brand selling compounded semaglutide or tirzepatide at one flat price across every dose
Editorial score · methodology
Broose Wellness
Best for: people who want compounded semaglutide or tirzepatide with lifestyle coaching and posted prices
Editorial score · methodology
Editorial score · methodology
Chronos Body Health & Wellness
Best for: physician-led GLP-1 care with brand-name and microdosing options
Editorial score · methodology
Get StartedRead full Chronos Body Health & Wellness review →Heros Health
Best for: Low, published prices on compounded semaglutide and tirzepatide with no membership fee
Editorial score · methodology
Hims
Best for: people who want brand-name GLP-1 pills or pens through a big-name app with 24/7 messaging
Editorial score · methodology
Editorial score · methodology
Iron Med RX
Best for: oral or injectable compounded GLP-1, one provider, account-gated pricing
Editorial score · methodology
Ironvale RX
Best for: compounded GLP-1s with nausea medicine bundled in and no charge unless a clinician approves you
Editorial score · methodology
KairoRx
Best for: people who want compounded GLP-1s alongside peptide and hormone treatments from one telehealth brand
Editorial score · methodology
Kairos Aesthetic and Longevity Medicine
Best for: Irving/Dallas patients wanting in-person, physician-led weight loss care
Editorial score · methodology
Get StartedRead full Kairos Aesthetic and Longevity Medicine review →Editorial score · methodology
Mochi Health
Best for: insurance help for brand-name GLP-1s, or self-pay compounded GLP-1 priced by dose
Editorial score · methodology
Editorial score · methodology
Ro
Best for: FDA-approved brand GLP-1s, including the Wegovy pill and Foundayo, with insurance help
Editorial score · methodology
Robinhood Telehealth
Best for: budget compounded semaglutide or tirzepatide with flat dose pricing and a microdose option
Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
SUROS Rx
Best for: published monthly and quarterly compounded GLP-1 prices with a named medical group and pharmacy
Editorial score · methodology
The Protocole
Best for: people who want compounded semaglutide or tirzepatide alongside other peptide therapies in one place
Editorial score · methodology
Tomorrow
Best for: people who want compounded GLP-1 injections or under-the-tongue drops on a true monthly plan
Editorial score · methodology
TomorrowsRX
Best for: people who want low per-month prices on prepaid compounded semaglutide or tirzepatide supplies
Editorial score · methodology
Editorial score · methodology
Vyvron
Best for: a locked founding rate from a platform that names its clinical partner and holds a real LegitScript seal
Editorial score · methodology
Frequently Asked Questions
Key terms, explained
New to GLP-1s? Tap any term for a quick, plain-English definition.
- Wegovy · Drugs and brands
- Zepbound · Drugs and brands
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Prior authorization (PA) · Insurance and regulatory
- Step therapy · Insurance and regulatory
- Off-label use · Insurance and regulatory
- Compounded GLP-1 · Pharmacy and drug forms
Cigna Coverage Updates
Get notified when Cigna GLP-1 coverage rules change.
Sources & methodology (as of November 2026)
- 1.KFF — Employer Health Benefits Annual Survey— Kaiser Family Foundation.
- 2.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
- 3.CMS — Medicare Part D Prescription Drug Coverage Program— Centers for Medicare & Medicaid Services.
- 4.CMS — Medicaid prescription drug coverage policy (state-by-state)— Centers for Medicare & Medicaid Services.
- 5.IRS Publication 502 — Medical and Dental Expenses (HSA/FSA eligibility)— Internal Revenue Service.
- 6.U.S. Department of Labor — ERISA and Employer Health Plans— U.S. Department of Labor, Employee Benefits Security Administration.
- 7.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 8.Weight Loss Rankings insurer coverage index (manually curated formulary data)— Weight Loss Rankings.